Endo180 (MRC2), a receptor enriched on myCAFs, has been shown to suppress CD8+ T cell infiltration and limit the efficacy of αPD-1/αCTLA-4 in murine models and melanoma patients [150]. This evidence concerns the gene MRC2 and melanoma.